Latest From Mesoblast Ltd.
Australian venture with Phase II-ready cell therapy in sights of Sumitomo Dainippon as Japanese firm looks to build regenerative medicine interests and pipeline ahead of major expiry.
Keeping Track: A Busy Week For Regenerative Medicine, A Surprise Priority Review For Vascepa, And Tazemetostat Aims For Accelerated Approval
The latest drug development news and highlights from our US FDA Performance Tracker.
A controversial cell therapy for spinal injuries receives coverage under Japan’s national health scheme, amid signs that the pricing of regenerative therapies may come under more scrutiny, while the first CAR-T treatment in the country takes a step closer to market.
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Parent & Subsidiaries
- Mesoblast Ltd.
- Senior Management
Silviu Itescu, CEO & Mng. Dir.
Paul Hodgkinson , CFO
Fred Grossman, MD, CMO
- Contact Info
Phone: (61) 3 9639 6036
55 Collins St.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.